The management of severe sepsis includes the use of agonists of α- and β-adrenergic, as well as of dopaminergic, receptors. Data suggest that the severe inflammatory immune response seen in sepsis can be modulated by stimulation and inhibition of these receptors both in vitro and in vivo. Specifically, release of tumor necrosis factor and interleukins can clearly be modified. Thus, pharmacologic agents directed at circulatory support may have significant potential for immunomodulation. Since the vasopressor and inotrope support of sepsis is not well standardized, variability in the resulting inflammatory mediator response may have consequences to the efficacy of new immunotherapies. This article provides an overview of the effect of the sympathetic nervous system activity and of receptor manipulation on cytokine response to endotoxin, and adds to the perspective on inhibition of phosphodiesterase in the therapy of septic shock.
|Number of pages||13|
|Journal||New Horizons: Science and Practice of Acute Medicine|
|Publication status||Published - Jun 18 1996|
- adrenergic receptors
- dopaminergic receptors
ASJC Scopus subject areas
- Critical Care and Intensive Care Medicine